Exosomes from coffee, ginkgo and ginseng

Plant-derived exosomes from coffee, ginkgo biloba, and ginseng address the limitations of large extracts by penetrating the blood-brain barrier and improving cognitive function and cell viability, providing a novel treatment for Alzheimer's disease.

JP2024542347AInactive Publication Date: 2024-11-15アイ エクソキュア ティビ ウルンラー サナイ ヴェ ティカレット アノニム シルケッティ
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024510259
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing coffee and ginseng extracts are large and unable to penetrate the blood-brain barrier effectively, limiting their therapeutic potential for Alzheimer's disease, while human-derived exosomes pose genetic risks.

Method used

Utilizing plant-derived exosomes from coffee, ginkgo biloba, and ginseng to create small nanoparticles that can penetrate the blood-brain barrier and treat Alzheimer's disease symptoms, formulated into pharmaceutically usable tablets.

Benefits of technology

The exosomes enhance cognitive function, alleviate symptoms such as amnesia and concentration difficulties, and increase cell viability in neuronal cells, offering a safer and more effective treatment than conventional extracts.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542347000002
    Figure 2024542347000002
  • Figure 2024542347000003
    Figure 2024542347000003
  • Figure 2024542347000004
    Figure 2024542347000004
Patent Text Reader

Abstract

Exosomes from coffee, ginkgo and ginseng The present invention relates to obtaining exosomes from coffee, ginkgo and ginseng plants and preparing tablets from them. The present invention relates to the use of plant-derived exosomes obtained from coffee, ginkgo and ginseng, which have high biocompatibility, cellular uptake, stability and a much greater ability to penetrate the blood-brain barrier, in the treatment and alleviation of symptoms of Alzheimer's disease; and in the treatment of cognitive dysfunction, amnesia and concentration impairment disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to obtaining exosomes from coffee, ginkgo and ginseng plants and preparing tablets therefrom.

[0002] The present invention relates to the use of plant-derived exosomes obtained from coffee, ginkgo and ginseng, which have high biocompatibility, cellular uptake, stability and much more ability to penetrate the blood-brain barrier, in the treatment and alleviation of symptoms of Alzheimer's disease; treatment of cognitive dysfunction, amnesia and concentration loss disorders. [Background technology]

[0003] Exosomes are natural nanoparticles of 30-150 nm size secreted by almost all cells. These nanoparticles have a membrane with a double lipid layer and proteins bound to the membrane. In addition, they contain materials such as miRNA, DNA, and proteins that convey the properties of the cell from which they are derived. Exosomes derived from certain cells have a natural targeting potential due to the proteins contained in their membrane. There are limitations and drawbacks to the use of exosomes obtained from human cells, since genetic material can alter the phenotypic and genotypic characteristics of the target cell. For these reasons, plant-derived exosomes have been increasingly investigated recently.

[0004] Plant-derived exosomes are small vesicles released by multivascular bodies primarily for cell-cell communication and immune control against pathogen attack. Studies conducted in the literature have shown that these nanoparticles can be absorbed by intestinal macrophages and exhibit interspecies communication by inducing multiple cytokines. The importance of plant-derived exosomes stems from their biomolecular content (lipids, proteins, and miRNAs), their easy internalization by mammalian cells, their anti-inflammatory, immunomodulatory, and regenerative properties. Plant-derived exosomes have the advantages of large-scale production, low toxicity, reduced immunogenicity, efficient cellular uptake, high biocompatibility, and stability. Due to these characteristics, there has been an increased interest in their potential applications in medicine, leading to in vitro and in vivo studies in this field.

[0005] Alzheimer's disease, the most common type of dementia, is defined as a slowly progressive neurodegenerative disorder characterized by neuritic plaques and neurofibrillary tangles as a result of the accumulation of Aβ peptides in the medial temporal lobe and neocortical structures. Although investigations continue as to whether Aβ plaques are the cause or consequence of Alzheimer's disease, it is believed that the increased toxic effects associated with the overproduction and accumulation of Aβ peptides are the primary cause of neurodegeneration and cognitive impairment.

[0006] Coffee is one of the most widely consumed beverages worldwide. Coffee contains many bioactive compounds, such as polyphenols, especially chlorogenic acid (CGA), caffeic acid, alkaloids (caffeine and trigonelline), and diterpenes (cafestol and kahweol). Studies conducted in the literature have shown that coffee consumption reduces the risk of developing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and dementia. Experimental studies on animals and humans have shown that various coffee extracts can alleviate the symptoms of Alzheimer's disease.

[0007] Clinical studies support the use of coffee to stimulate the production of brain-derived neurotrophic factor (BDNF). BDNF has powerful effects on the brain and central nervous system. By regulating the development and differentiation of new neurons, BDNF ensures neuronal survival and supports stable mood. BDNF production decreases with age and is observed at low levels in patients diagnosed with Alzheimer's disease. In one study, a single dose of encapsulated coffee concentrate was shown to increase peripheral serum BDNF by 91% at 60 minutes and 66% at 120 minutes compared to initial levels.

[0008] Ginseng has traditionally been used in Oriental medicine (traditional Oriental medicine) to treat many diseases. Studies conducted in the literature have shown that the ingestion of ginseng extracts can alleviate the symptoms of Alzheimer's disease and can lead to improved cognitive function. Ginseng extracts are known to contain biologically active components that can prevent cognitive dysfunction. It has been stated that biologically active chemicals within ginseng extracts can prevent cognitive dysfunction by reducing Aβ formation and aggregation. There are also studies in the literature that show that these extracts improve Aβ-induced mitochondrial damage and contribute to the reduction of anti-apoptotic protein levels.

[0009] In their study, Park et al. reported improvement in cognitive function due to ginseng intake in volunteers with cognitive dysfunction.

[0010] Ginkgo is also used as a standardized extract to treat a variety of problems, including concentration problems, memory, confusion, depression, anxiety, dizziness, tinnitus, and headaches. Ginkgo's main use is in treating brain dysfunction. Ginkgo is recommended to slow the progression of neurodegenerative diseases, such as age-related cognitive decline, Alzheimer's disease, and other types of dementia.

[0011] Due to the large size of the extracts obtained from coffee, ginkgo and ginseng, they are unlikely to penetrate the blood-brain barrier. These properties of the extracts obtained from coffee, ginkgo and ginseng limit the effectiveness of these extracts in treating Alzheimer's disease.

[0012] The action of coffee, ginkgo and ginseng on the treatment of Alzheimer's disease and on the activity of cognitive function and concentration has been explored using essences and extracts. However, studies on their use at the exosomal level are not included in the literature and there are no patents available in this field. It is clear that exosomes derived from coffee, ginkgo and ginseng, offering an innovative perspective on the solution of Alzheimer's disease that differs from traditional methods, are a source of new hope for those fighting the disease in terms of preventing the formation of Aβ plaques, a pathological symptom of the disease. In this context, the first use of exosomes obtained from coffee, ginkgo and ginseng and the fact that it explores the possibility of treating Alzheimer's disease in this context, distinguish it from other patents derived from coffee, ginkgo and ginseng for the treatment of this disease.

[0013] As a result, due to the above-mentioned negative aspects and due to the inadequacies of existing solutions on the subject matter, improvements in the related art have become necessary. Summary of the Invention

[0014] The present invention relates to exosomes obtained from coffee, ginkgo and ginseng, which meet the above mentioned requirements, eliminate all the drawbacks and provide some additional advantages.

[0015] The main objective of the present invention is to provide a treatment and relief of symptoms of Alzheimer's disease in patients with said disease by using exosomes obtained from coffee, ginkgo and ginseng.

[0016] The main objective of the present invention is to provide a treatment for cognitive impairment, memory impairment and concentration difficulties by using exosomes obtained from coffee, ginkgo and ginseng.

[0017] Another object of the present invention is to provide the use of natural products with extremely low toxicity and side effects instead of synthetic molecules in the treatment of Alzheimer's disease and to enhance cognitive function and concentration.

[0018] Another object of the present invention is to enable exosomes obtained from coffee, ginkgo and ginseng to penetrate the blood-brain barrier much more due to their small size.

[0019] In order to achieve the above-mentioned objectives, the present invention relates to the use of coffee, ginkgo and ginseng plants in obtaining exosomes.

[0020] In order to achieve the above-mentioned objectives, the present invention includes the use of exosomes obtained from coffee, ginkgo and ginseng plants in the treatment of Alzheimer's disease, cognitive impairment, memory impairment (amnesia) and concentration difficulties.

[0021] The present invention is plant-derived exosomes, including their use in treating Alzheimer's disease patients to alleviate amnesia and other symptoms.

[0022] The present invention relates to exosomes derived from plants, including their use in enhancing cognitive function and concentration. To achieve the above-mentioned objectives, the present invention relates to exosomes for use in the treatment of Alzheimer's disease, cognitive impairment, memory impairment (amnesia) and concentration difficulties, including from coffee, ginkgo and ginseng plants.

[0023] The present invention is a plant-derived exosome, which is in the form of a pharma-ceutical usable tablet.

[0024] The structural and characteristic features of the present invention and all of its advantages will be more clearly understood from the figures presented below and the detailed description given with reference to these figures, and should be evaluated in light of these figures and the detailed description. [Brief description of the drawings]

[0025] [Figure 1] SEM image of exosomes extracted from coffee.

[0026] [Diagram 2] 1 is a graph showing the diameter distribution of exosomes obtained from coffee.

[0027] [Diagram 3] This is an SEM image of exosomes obtained from ginseng.

[0028] [Figure 4] Another SEM image of exosomes obtained from ginseng.

[0029] [Diagram 5] 1 is a graph showing the distribution of diameters of exosomes obtained from ginseng.

[0030] [Figure 6] Another SEM image of exosomes obtained from ginkgo biloba.

[0031] [Figure 7] 1 is a graph showing the distribution of diameters of exosomes obtained from ginkgo biloba.

[0032] [Figure 8] FIG. 1 is a graph showing the effect of coffee exosomes applied at different concentrations to HT-22 cells on cell viability.

[0033] [Figure 9]FIG. 1 is a graph showing the effect of coffee, ginseng and ginkgo exosomes applied in combination at different concentrations to HT-22 cells on cell viability.

[0034] [Figure 10] 1 is a graph showing the effect of different concentrations of Aβ(1-42) on cell viability of HT-22 cells.

[0035] [Figure 11] FIG. 13 is a graph showing the effect of coffee exosomes applied at different concentrations to HT-22 cells formed with established Aβ(1-42) toxicity on cell viability.

[0036] [Figure 12] 1 is a graph showing the effect of ginseng exosomes applied at different concentrations on cell viability of HT-22 cells.

[0037] [Figure 13] FIG. 1 is a graph showing the effect of ginseng, coffee, and ginkgo exosomes applied in combination at different concentrations to HT-22 cells on cell viability.

[0038] [Figure 14] FIG. 1 is a graph showing the effect of ginseng exosomes applied at different concentrations to HT-22 cells with established Aβ(1-42) toxicity on cell viability. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] In this detailed description, the plant-derived exosomes obtained from coffee, ginkgo and ginseng, which are the subject of the present invention, are described solely for a better understanding of the subject matter, in a manner such that they do not produce any limiting effect.

[0040] The present invention relates to the use of coffee, ginkgo and ginseng plants to obtain exosomes.

[0041] The present invention also relates to the use of exosomes derived from coffee, ginkgo and ginseng plants in the treatment of Alzheimer's disease, cognitive impairment, amnesia (memory disorders) and concentration disorders.

[0042] Exosomes used to treat Alzheimer's disease, cognitive impairment, amnesia and concentration disorders include those from coffee, ginkgo and ginseng plants.

[0043] The plant-derived exosomes that are the subject of the present invention are used in the treatment of Alzheimer's disease, particularly in patients with said disease, to reduce amnesia and other symptoms.

[0044] The plant-derived exosomes that are the subject of the present invention are also used to enhance cognitive function and concentration. According to a preferred embodiment of the present invention, the plant-derived exosomes that are the subject of the present invention are in the form of a tablet that can be used pharmaceutical.

[0045] In the method for producing exosomes to be used for the symptomatic relief and treatment of Alzheimer's disease in patients with said disease, which is the subject of the present invention, differential centrifugation is used for the isolation of exosomes obtained from coffee, ginkgo and ginseng.

[0046] The method for producing exosomes obtained from coffee, ginkgo and ginseng that is the subject of the present invention comprises the following process steps: i. Brewing or blending plant extracts and obtaining an extract; ii. Centrifugation of the solution in a stepwise manner at different gravities and durations; iii. Removal of the pellet by removing the supernatant obtained after each centrifugation step; iv. The resulting pellet obtained after the final centrifugation is slowly dissolved in 1 ml of PBS; v. Transfer the lysed pellets to tubes and store them at approximately -80°C.

[0047] According to a preferred embodiment of the present invention, the differential centrifugation stages applied in process step (ii) of the production method are respectively as follows: a. Centrifuge the sample at 200 g for approximately 10 minutes; b. Centrifuge the resulting supernatant at 2000 g for approximately 20 minutes; c. Centrifuge the resulting supernatant at 10,000 g for approximately 30 minutes; d. The resulting supernatant is centrifuged at 150,000 g for approximately 90 minutes.

[0048] Table 1 below shows the properties and effects of exosomes, the subject of the present invention. [Table 1] Table 1: Characteristics of exosomes Experimental studies relating to the present invention are described in detail below.

[0049] Exosome isolation by differential centrifugation:

[0050] The samples were centrifuged at 200g for 10 minutes and the pellet was discarded by collecting the supernatant obtained after centrifugation. The resulting supernatant was centrifuged at 2000g for 20 minutes and the pellet was discarded by collecting the supernatant obtained after centrifugation. The resulting supernatant was centrifuged at 10,000g for 30 minutes and the pellet was discarded by collecting the supernatant obtained after centrifugation. The resulting supernatant was centrifuged at 150,000g for 90 minutes and the supernatant obtained after centrifugation was discarded and the pellet was slowly dissolved in 1 ml of PBS and transferred to an Eppendorf tube. The samples were stored at -80°C and kept until the working day.

[0051] SEM (Scanning Electron Microscopy) analysis and determination of exosome diameter distribution:

[0052] The diameter distribution of exosomes obtained from coffee, ginkgo and ginseng was analyzed by SEM. SEM analysis is one of the best methods to obtain quantitative and qualitative information about porous structures. It is widely used in determining the average pore size and distribution. First, the exosomes were washed with PBS solution and fixed with 2.5% glutaraldehyde solution. Then, the samples were washed with PBS to remove the glutaraldehyde. The samples were dehydrated with increasing concentrations of ethanol from 30% to 100%. Then, the samples were dried at room temperature and photographed at different positions with appropriate magnification at high resolution. The diameter distribution of exosomes in the obtained images was measured with the help of Image J program (randomly selected within the SEM grid).

[0053] Bradford Protein Assay

[0054] Standards were prepared in Eppendorf tubes according to the Bradford Protein Assay Kit procedure. 5 μL of the prepared standards were added to each well from the exosome samples obtained from coffee, ginkgo, and ginseng. Then, 200 μL of Bradford reagent solution was added to each well and pipetted. The standards and samples were incubated at room temperature for 15 minutes. The absorbance values ​​of the standards and samples were measured at a wavelength of 570 nm using a microplate reader. A standard curve was drawn according to the absorbance values ​​obtained from the standards, and the amount of protein for each sample was calculated.

[0055] HT-22 cell culture and WST-1 cell viability assay:

[0056] Cells were grown at 37°C in a feed yard in an environment of 95% humidity and 5% CO2, with 10% fetal bovine serum (Invitrogen), 2 mm glutamine, 100 units / ml penicillin, and 100 mg / ml streptomycin in DMEM (Dulbecco's Modified Eagle's Medium) (pH: 7.2-7.4). Cell viability and cell number were determined using a hemocytometer with 0.4% trypan blue dye. Non-viable cells absorb trypan blue dye and their nuclei appear blue under the light microscope. In this way, non-viable cells can be counted separately from viable cells. In all experiments, the percentage of viable cells was determined before the start of the experiment as (percent viable cells = number of cells not receiving dye / total number of cells x 100) and started at the value at which cell viability was 95%. HT-22 cells were incubated with exosomes from coffee, ginkgo, and ginseng at concentrations of 1-50 μg / ml for 24 hours. After 24 hours of incubation, the cell viability of HT-22 cells was analyzed by WST-1 assay. Before performing the WST-1 viability assay, a WST-1 stock solution was prepared and 100 μl of the solution was applied to each well from the stock solution. The cells were then incubated for 2 hours. After 2 hours of incubation, the absorbance was measured at a wavelength of 450 nm using a microplate reader.

[0057] Construction of an in vitro Alzheimer's disease model with Aβ(1-42) toxicity:

[0058] Lyophilized Aβ(1-42) peptide was dissolved in distilled water and DMSO to prepare a 1 mM stock solution. The prepared stock solution was serially diluted by preparing Aβ(1-42) solutions at different contractions (2.5 μM, 5 μM, 10 μM, 25 μM, and 50 μM). HT-22 cells were placed in each well at 10 4Cells were seeded in 96 plates at 1000 cells / ml. The cells were incubated with different concentrations (5 μM, 10 μM, 25 μM, and 50 μM) of Aβ(1-42) peptide for 24 hours. After incubation, a WST-1 cell viability test was performed to determine the cell viability of the cells and to determine the effective dose of Aβ(1-42). In an in vitro Alzheimer's disease model created by the inventors using Aβ(1-42) toxicity at effective doses in HT-22 cells, the cells were incubated with exosomes derived from ginseng and coffee at concentrations of 5 to 50 μg / ml for 24 hours, and the cell viability of the cells was determined after 24 hours of incubation.

[0059] The results of the experimental study are discussed below.

[0060] When coffee exosomes at different concentrations (1-50 μg / ml) were applied alone or in combination with ginkgo and ginseng exosomes, a statistically significant increase in cell viability of hippocampal neuronal cells was observed (p<0.05) compared to the cell viability of control cells without exosome application.Similarly, when ginseng exosomes at different concentrations (1-50 μg / ml) were applied alone or in combination with coffee and ginkgo exosomes, a statistically significant increase in cell viability of hippocampal neuronal cells was observed (p<0.05) compared to the cell viability of control cells without exosome application.

[0061] In the second stage of the study, an in vitro Alzheimer's disease model with Aβ(1-42) toxicity was created in HT-22 cells. Exosomes obtained from coffee and ginseng at concentrations of 1-50 μg / ml were applied to cells with induced Aβ(1-42) toxicity and changes in their cell viability were analyzed. Exosomes obtained from coffee at concentrations of 1-50 μg / ml significantly increased cell viability of cells with Aβ(1-42) toxicity (p<0.05). Exosomes obtained from ginseng at a concentration of 10 μg / ml significantly increased cell viability of cells with Aβ(1-42) toxicity (p<0.05).

[0062] In summary, exosomes derived from coffee, ginkgo and ginseng significantly increased cell proliferation both in healthy hippocampal neuronal cells and in neuronal cells within the hippocampus region of the brain associated with memory, where Aβ(1-42) toxicity has been established.

[0063] These results indicate that exosomes obtained from coffee, ginkgo and ginseng can be used to treat; - in Alzheimer's disease, for the treatment of said disease and for the relief of symptoms; and - Cognitive impairment, amnesia (memory disorder) and difficulty concentrating

[0064] Exosomes obtained from coffee, ginkgo and ginseng have a much higher ability to penetrate the blood-brain barrier due to their small size. Due to these characteristics, exosomes derived from coffee, ginkgo and ginseng may exhibit much higher biological activity than larger structures such as extracts. The subject matter of the present invention, exosomes derived from coffee, ginkgo and ginseng, will be much more effective than existing coffee, ginkgo and ginseng extracts in treating Alzheimer's disease and in treating cognitive dysfunction, amnesia and concentration difficulties.

Claims

1. Obtaining exosomes using coffee, ginkgo and ginseng plants.

2. Use of exosomes obtained from coffee, ginkgo and ginseng plants in the treatment of Alzheimer's disease, cognitive dysfunction, memory impairment and concentration impairment disorders.

3. The use according to claim 2, wherein the plant-derived exosomes are used for the treatment of Alzheimer's disease and for the alleviation of amnesia and other symptoms.

4. The use according to claim 2, wherein the plant-derived exosomes are used to improve cognitive function and concentration.

5. Exosomes containing coffee, ginkgo and ginseng plants for the treatment of Alzheimer's disease, cognitive impairment, amnesia and concentration loss disorders.

6. The plant-derived exosome according to claim 5, which is in the form of a medicamentously usable tablet.

Citation Information

Patent Citations

  • Brain function improving composition

    JP2018070464A

  • Composition for preventing hair loss or promoting hair growth containing exosome-like vesicles derived from ginseng

    JP2018530546A

  • Plant-derived extracellular vesicle (EV) compositions and uses thereof

    JP2022525131A

  • Composition, antioxidant agent, antisaccharification agent, neurite outgrowth promoter, and cognitive function improver

    WO2021085496A1